Immunosuppressive therapy after human lung transplantation
Authors:
- C. KnoopCKC. Knoop
- A. HaverichAHA. Haverich
- S. FischerSFS. Fischer
Open Access
- 1 January 2003
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 23 (1) , 159-171
Abstract
In 2002, equal numbers of lung transplantation (LTx) were performed with or without induction therapy with antilymphocyte antibodies, monoclonal anti-CD3 antibody or anti-interleukin‐2‐receptor monoclonal antibodies. It remains to be established if induction therapy after LTx is beneficial or deleterious for long-term graft and patient survival.The vast majority of lung transplant recipients receive a triple-drug maintenance regimen including a calcineurin inhibitor, a cell-cycle inhibitor and steroids. Equal proportions receive cyclosporin A (CsA) and tacrolimus (Tac). There is also a trend to prescribe mycophenolate mofetil (MMF) instead of azathioprine (Aza). Steroid withdrawal is uncommon even 5 yrs after transplantation.The superiority of Tac over CsA as a maintenance agent has not been established to date, and the administration of MMF instead of Aza in combination with CsA and steroids did not improve graft or patient survival in a recent international, prospective, randomised, controlled trial.Shift from cyclosporin A to tacrolimus has emerged as the first treatment step of refractory acute rejection followed by high-dose steroids or antilymphocyte agents, total lymphoid irradiation or photopheresis. The treatment of chronic rejection remains deceptive and includes varied strategies such as modification of the maintenance regimen, addition of inhaled immunosuppressants and/or total lymphoid irradiation and photopheresis.Keywords
This publication has 97 references indexed in Scilit:
- Surveillance transbronchial lung biopsies: Implication for survival after lung transplantationThe Journal of Thoracic and Cardiovascular Surgery, 2000
- Induction immunosuppression for lung transplantation with OKT3The Annals of Thoracic Surgery, 1999
- Pharmacokinetic Profile and Variability of Cyclosporine versus Neoral in Patients with Cystic Fibrosis after Lung TransplantationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1998
- Mycophenolate Mofetil for Obliterative Bronchiolitis Syndrome After Lung TransplantationThe Annals of Thoracic Surgery, 1997
- Clinical trial of tacrolimus versus cyclosporine in lung transplantationThe Annals of Thoracic Surgery, 1995
- Obliterative bronchiolitis after lung and heart-lung transplantationThe Journal of Thoracic and Cardiovascular Surgery, 1995
- FK506 conversion for intractable rejection of the liver allograftTransplant International, 1993
- An evaluation of the role of omentopexy and of early perioperative corticosteroid administration in clinical lung transplantationThe Journal of Thoracic and Cardiovascular Surgery, 1993
- Acute rejection of lung allografts with various immunosuppressive protocolsThe Annals of Thoracic Surgery, 1992
- Biological effects of cyclosporin A: A new antilymphocytic agentInflammation Research, 1976